Alternativa terapéutica para el dolor pélvico crónico de origen vesical / New approach in treatment of pelvic chronic pain syndrome (CPPS)

Introducción: El dolor pélvico crónico (DPC) es un problema complejo e importante tanto por su frecuencia como por sumorbilidad. Cuando se presenta asociado con síntomas miccionales deberemos pensar en un origen vesical. Objetivo: Evaluar la respuesta a un tratamiento intravesical, al que denominamos Formula Sedante, en pacientes con dolor pélvico crónico de origen vesical, refractarios a otros tratamientos. Material y métodos: Entre junio 2005 y septiembre de 2008, 14 pacientes (edad media de 59 años), 12 mujeres y 2 hombres, con DPC de origen vesical siguieron un tratamiento intravesical con “Formula Sedante”, como terapia de segunda línea. Su composición es Dexametasona, Nitrofurantoína, Lidocaína y Suero salino. Evaluamos el dolor (escala 0-10), la frecuencia miccional y la mejoría subjetiva del paciente. Resultados: El dolor global medio fue de 6’4 de base, al mes y a los 6 meses fue de 4’7 y 3’5 respectivamente. El 75% de los pacientes mostró una disminución de los valores en la escala de dolor. La frecuencia miccional diurna mejoró un 28%al mes del tratamiento y un 40% a los 6 meses. Un 70 % de los pacientes refirió sentir mejoría tras la pauta de instilaciones, de los cuales en torno a un 80% la evaluó como “moderadamente mejor” o “mucho mejor”, tanto al mes como a los 6 meses del tratamiento. Ninguno de los pacientes presento efectos secundarios reseñables. Conclusiones: Consideramos el tratamiento de instilación intravesical con “Formula Sedante” una opción útil y segura, como segunda línea de tratamiento, para el dolor pélvico crónico de origen vesical (AU)

Introduction: Chronic pelvic pain syndrome (CPPS) is a complex problem that is a major cause of morbidity and disability. Objetive: To evaluate the feasibility, safety and efficacy of intravesical instillation of a new therapeutic tool in patients suffering from CPPS. Methods: Between june 2005 and september 2008 we recruited 14 patients (mean age 59) who had been diagnosed with CPPS, and refractory to previous treatments. The intravesical solution consisted of steroids, local anaesthetic, antibiotic and saline solution. Was evaluated the intensity of pain; voiding frequency and subjective improvement (with patient global improvement impression PGI-I).Results: Global pain at baseline was 6,4, at 1 month and 6 months 4,7 and 3,5. 75% of the patients showed improvement in the reduction of pain. Voiding frequency at baseline was 22’5 daily. At one and six months, voiding frequency was 16,2and 13,5 respectively. According to the PGI-I test 30% of patients were much better, 30% moderate improvement, 10%slight improvement and 30% with no changes at 1 month. At 6 months, 15% of patients were much better, 40% moderated improvement, 15% slight improvement and 30% with no changes. None of the patients felt worse than before treatment. Conclusions: Therapeutic results of our intravesical solution traduces in an improvement of pain and voiding frequency reduction with no side-effects. Patients benefit of this improvement in the PGI-I test that reflects an improvement in quality of life. We consider this treatment a second-line approach for CPPS in which gold standard management is still a challenge (AU)

[Cavernous hemangioma of the bladder]. / Cavernomatosis vesical: una patologia infrecuente.

OBJECTIVE: Certain pathologic entities should be ruled out in the diagnostic work up of hematuria, because they are so rare that if they would not share diagnostic tests with more frequent urological diseases they could be missed. The cavernous haemangioma of the bladder is one of them. METHODS: We report the case of a male patient presenting with rectal bleeding and hematuria with the diagnosis of rectal-vesical cavernous haemangioma. RESULTS: After 8 years of follow-up he did not need surgical treatment, only blood transfusions at the time of diagnosis. He has self limited episodes of hematuria not requiring aggressive therapy. CONCLUSIONS: The cavernous haemangioma of the bladder is a rare disease presenting as bleeding bladder excrecent lesions that do not require surgery as first treatment option if the bleeding is not life-threatening.

Cavernomatosis vesical: una patología infrecuente / No disponible

OBJETIVO: Existen ciertas patologías a tener en cuenta en el estudio de una hematuria, que por su infrecuencia pasarían desapercibidas de no ser porque comparten pruebas diagnosticas con las patologías urológicas más comunes; una de ellas es la cavernomatosis vesical. MÉTODO: Presentamos el caso de un paciente que debutó con rectorragias y hematuria y fue diagnosticado de cavernomatosis rectovesical. RESULTADOS: Después de 8 años de seguimiento de su hematuria no ha requerido tratamiento quirúrgico alguno y solamente ha precisado de transfusión al inicio del diagnóstico. Los episodios de hematuria son autolimitados y no requieren maniobras agresivas. CONCLUSIONES: La cavernomatosis vesical es una patología infrecuente que se manifiesta en forma de lesiones vesicales excrecentes que sangran y que no requiere tratamiento quirúrgico de entrada si no compromete la vida del paciente (AU)

OBJECTIVE: Certain pathologic entities should be ruled out in the diagnostic work up of hematuria, because they are so rare that if they would not share diagnostic tests with more frequent urological diseases they could be missed. The cavernous haemangioma of the bladder is one of them. METHODS: We report the case of a male patient presenting with rectal bleeding and hematuria with the diagnosis of rectalvesical cavernous haemangioma. RESULTS: After 8 years of follow-up he did not need surgical treatment, only blood transfusions at the time of diagnosis. He has self limited episodes of hematuria not requiring aggressive therapy. CONCLUSIONS: The cavernous haemangioma of the bladder is a rare disease presenting as bleeding bladder excrecent lesions that do not require surgery as first treatment option if the bleeding is not life-threatening (AU)

[Hand-assisted laparoscopic radical nephrectomy vs. open nephrectomy in the treatment of clinically localized renal cell carcinoma. Comparative study]. / Nefrectomía radical laparoscópica asistida por la mano frente a nefrectomía abierta en el tratamiento del carcinoma de células renales clínicamente localizado. Estudio comparativo.

INTRODUCTION: The description of the first laparoscopic nephrectomy made a revolution in the managing of the benign and malignant renal diseases. Hand-assisted laparoscopy (HAL) was developed with the aim of offering advantages to both patients and surgeons. The aim of the present work is to compare, in our experience, the results offered in the radical nephrectomy by HAL and open surgery, by analysis of surgical time, estimated blood loss during surgery and hospital stay. METHODS: Eleven Hand-assisted laparoscopic (HAL) radical nephrectomies and eight open radical nephrectomies were carried out at our institution during the same period (June 2001 to December 2002). All patients underwent computed tomography and were found to have a clinically localised functioning renal mass in all cases. The size of this renal mass was 4-7 cm (average 5.5 cm) in the HAL group and 4.5-15 cm (average 7.8 cm) in the open group. Patient age, body mass index, and American Society of Anaesthesiologists' score showed no significant difference between groups. RESULTS: The average surgical time in the HAL group was 156.72 minutes, the average blood loss during surgery was of 83.6 ml and the average hospital stay was of 3.09 days. Conversion to open surgery was not necessary in any patient. Average surgical time in the open surgery group was 178.25 minutes, the estimated blood loss during surgery was of 337.75 ml (p < 0.05) and the hospital stay was of 5.37 days (p < 0.05). The comparison of the means by two-tailed student's t test revealed significant differences in estimated blood loss and hospital stay, favoring HAL, and no significant differences in surgical time. CONCLUSIONS: HAL nephrectomy is feasible in almost all nephrectomies and is a safe, reproducible, and minimally invasive technique to perform extirpable renal surgery. HAL offer clear advantages over traditional open surgery, including decreased blood loss and hospital stay.